Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield MI Medicare Formulary Cover…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentblue cross blue shield - michiganPolicy N/A

    2026 Healthy Value Comprehensive Formulary (Medicare drug list)

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the Medicare Plus Blue Group PPO and Prescription Blue Group PDP 2026 formulary describing covered prescription drugs, member cost-sharing, and coverage rules (prior authorization, step therapy, quantity limits) that apply to plan members and prescribers.

    Policy Summary
    Payerblue cross blue shield - michigan
    Policy2026 Healthy Value Comprehensive Formulary (Medicare drug list)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests when a drug is marked PA to avoid coverage denials.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    06/01/2026Formulary effective date
    $35Insulin max monthly cost
    31 daysTemporary supply
    PA indicatedPA present
    Multiple QLsQuantity limits

    Formulary Coverage Criteria

    General coverage conditions

    General formulary coverage and exception rules

    General coverage: The plan will generally cover drugs listed on the formulary when medically necessary, the prescription is filled at a network pharmacy, and other plan rules are followed.

    Based on formulary definition and scope

    Coverage restrictions: Some drugs have utilization controls such as Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST), Non-Extended Day Supply (NDS), or Oncology Value Management (OVM); these requirements must be met for coverage.

    See formulary table and definitions for per-drug codes

    Denial risk: If required prior authorization is not obtained or quantity limits are exceeded, the plan may not cover the drug.

    Providers should submit PA per plan rules

    Policy Summary
    Payerblue cross blue shield - michigan
    Policy2026 Healthy Value Comprehensive Formulary (Medicare drug list)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests when a drug is marked PA to avoid coverage denials.
    SourceLink
    On This Page
    Formulary Coverage CriteriaFormulary Drug Listings and CodingPrior Authorization, Step Therapy, Documentation, and Denial RiskStep Therapy Rules and Affected ProductsQuantity Limits and Per-Product ExamplesSite of Care and Infusion Center NotesBiosimilar and Interchangeable Biologic NotesBackground and Scope

    Transition/temporary coverage

    Transition and temporary coverage

    Temporary supply for non-formulary or newly restricted drugs: For each drug not on the 2026 formulary or with a new coverage restriction, the plan will cover a temporary 31-day supply while the member and prescriber pursue an exception or alternative.31 days

    Applies during first 108 days of membership; LTC emergency 31-day supply may apply after 108 days

    Notification: The plan will send a letter within three business days after dispensing a temporary transition supply explaining options and next steps.3 business days

    Operational communication to member

    Transition assistance during facility moves: When moving into or out of a long-term care facility or on hospital discharge, early refill limits may be waived to ensure medication access during the transition.

    Contact Customer Service for assistance; refer to Evidence of Coverage Chapter 5 for details

    Formulary exceptions

    Formulary exception requests

    Grounds for exception: A member or prescriber may request an exception to cover a non-formulary drug, to waive a coverage restriction (PA, ST, QL), or to obtain lower cost-sharing; the prescriber must explain the medical reasons why the formulary alternative or applying the restriction would not be as effective or would cause adverse effects.

    Exceptions may change tiering (covered on Tier 4 if approved)

    Decision timeframe: The plan will make a non‑expedited decision within 72 hours of receiving the prescriber’s supporting statement; expedited requests will be decided within 24 hours when clinically appropriate.72 / 24 hours

    Expedite when waiting could seriously harm the member

    How to request: You or your prescriber should contact the plan to request a formulary or tiering exception and provide supporting clinical documentation.

    See Evidence of Coverage for submission details

    Formulary coverage conditions

    Coverage is determined by drug-specific tier placement and plan codes; certain drugs require prior authorization, have quantity limits, or are subject to step therapy or oncology management.

    Prior Authorization (PA): Drugs marked PA require prior authorization before the plan will cover the drug.

    Example: ARIKAYCE listed with PA

    Quantity Limits (QL): Drugs with QL have a maximum covered amount within the specified time window; the exact QL is shown on the drug line.e.g., QL(31 EA per 31 days), QL(180 EA per 90 days)

    Refer to the formulary row for precise limit

    Step Therapy (ST): Drugs marked ST require trial of a preferred drug before the plan will cover the listed product.

    See formulary for products flagged ST

    Oncology Value Management (OVM): Antineoplastics and oncology supportive care drugs may require authorization via the OVM program and additional documentation.

    OVM administered by OncoHealth per definitions

    Non-Extended Day Supply (NDS): NDS indicates supply restrictions (e.g., many opioids limited to 30–31 day fills); follow the per-drug NDS annotation.typically 30–31 days

    See NDS in definitions

    General formulary coverage

    Coverage and access depend on the drug-specific 'Requirements/Limits' column:

    Formulary entry components: Each formulary row lists drug name/strength, Drug Tier, and Requirements/Limits (e.g., QL, PA, ST, NDS); coverage is contingent on meeting any listed requirements.

    Follow per-line Requirements/Limits for adjudication

    PA + QL combined controls: Some products combine PA and QL; providers must both obtain authorization and adhere to quantity limits for coverage.

    Examples in anticonvulsant and targeted therapy listings

    Operational documentation: When PA, ST, or NDS is indicated prescribers should supply supporting documentation (diagnosis, dose, prior therapy, quantity) per the plan's prior authorization program.

    Refer to PA program and Evidence of Coverage for submission details

    Formulary coverage summary

    Drugs are covered on the formulary with tier assignment and may have quantity limits or prior authorization as specified.

    Per-line coverage dependency: Coverage for a listed drug depends on its Drug Tier assignment and any Requirements/Limits shown (for example, QL values or PA flags).

    No product-specific clinical PA criteria are provided in this excerpt; follow the plan PA process when PA is indicated

    Insulins and select injectables: Some concentrated insulins and specialty injectables are listed with PA; providers must obtain PA for these products when indicated.

    Examples: HUMULIN R U-500 marked PA

    GLP-1 / antidiabetic agents: Certain GLP-1 injectables (e.g., MOUNJARO, OZEMPIC) have QL and PA annotations; adherence to these requirements determines coverage.e.g., QL(2 ML per 28 days); QL(3 ML per 28 days)

    See specific drug lines

    Coverage determination

    Coverage depends on formulary tier, quantity limits, and prior authorization where indicated.

    Tier + Utilization Controls: A drug's coverage status is determined by its placement on the formulary tier plus any Requirements/Limits such as QL or PA shown on the drug line.

    Examples include QL entries for Xarelto and PA requirements for hematology/supportive agents

    Hematology and supportive agents: Eltrombopag formulations, PROCRIT, ZARXIO and other blood agents have QL and/or PA annotations; these annotations must be satisfied for coverage.e.g., QL(186 EA per 31 days); PA

    Refer to the specific drug row for the exact QL/PA

    Formulary coverage rules

    Coverage is determined per listed product when member meets plan terms; the table indicates tier, any quantity limits (QL), and whether prior authorization (PA) is required.

    Product-level adjudication: For each product, coverage is allowed when the member meets the plan's terms (e.g., member is eligible, fills at network pharmacy) and any per-product Requirements/Limits are satisfied.

    Consult the formulary row for QL values and PA/ST/OVM flags

    Topical and dermatologic QLs: Many topical dermatology products have GM/ML quantity limits per 90 days (e.g., QL(360 GM per 90 days); QL(180 ML per 90 days)); dispensing must align with those QLs for coverage.e.g., QL(360 GM per 90 days)

    Examples: fluocinolone, fluocinonide, calcipotriene

    Potassium binders and packets: Packets such as LOKELMA and VELTASSA show specific QLs (e.g., QL(270 EA per 90 days)); these limits apply to coverage and dispensing frequency.e.g., QL(270 EA per 90 days)

    See packet-size specific QL on formulary rows

    If a drug is withdrawn from sale by the manufacturer or the FDA determines it must be withdrawn for safety or effectiveness reasons, the plan may immediately remove the drug from the formulary and it will not be covered. Members who take a removed drug will be notified and may be eligible to request an exception to continue coverage as described in the formulary notice process.

    Specialty (Tier 4/5) drugs are subject to different supply rules: a 90-day supply is not available for Specialty Tier drugs, and some Tier 5 products may be limited to a 31-day supply per fill. When changes are made, affected members may receive a 31-day supply and notice allowing time to pursue an exception or alternative.

    Within the provided extract there are no explicit exclusion statements listing drug products or classes that are categorically excluded from coverage; coverage determinations are presented at the individual drug line level via tier and Requirements/Limits annotations.

    The extract does not list any specific clinical exclusions. Clinical restriction and coverage are managed through per-product Requirements/Limits (e.g., PA, QL, ST) rather than broad clinical exclusion statements in this segment.

    No explicit medication exclusions are listed in this excerpt. The formulary uses product-level annotations (tier and Requirements/Limits) to indicate coverage conditions rather than a separate list of excluded medications in the provided pages.

    There are no 'Not Medically Necessary' statements

    This extract does not contain any statements declaring treatments or drugs as not medically necessary. Coverage guidance here is expressed through tiers and Requirements/Limits such as QL, PA, and ST.

    No 'not medically necessary' determinations appear in the provided excerpt. Review and coverage decisions are driven by the per‑product rules shown in the Requirements/Limits column.

    Formulary Drug Listings and Coding

    Formulary drug entriesmixed
    celecoxib capsule 200mg, 400mgDrug Tier = 3; Requirements/Limits = QL(180 EA per 90 days)
    celecoxib capsule 100mgDrug Tier = 3; Requirements/Limits = QL(270 EA per 90 days)
    celecoxib capsule 50mgDrug Tier = 3; Requirements/Limits = QL(540 EA per 90 days)
    diclofenac potassium tablet 50mgDrug Tier = 2
    diclofenac sodium dr tablet delayed release 25mg, 50mg, 75mgDrug Tier = 2
    diclofenac sodium er tablet extended release 24 hour 100mgDrug Tier = 2
    diclofenac sodium/misoprostol tablet delayed release 50mg;200mcg, 75mg;200mcgDrug Tier = 4
    diclofenac sodium external solution 1.5%Drug Tier = 4; Requirements/Limits = QL(600 ML per 30 days)
    diflunisal tablet 500mgDrug Tier = 3
    etodolac er tablet extended release 24 hour 400mg, 500mg, 600mgDrug Tier = 3
    1–10 of 29
    1/3
    Formulary drug entries from chunksmixed
    NICOTROL NS SOLUTION 10MG/MLDrug listed on formulary (Tier 4)
    varenicline tartrate tablet 0.5mg, 1mgDrug listed on formulary (Tier 4)
    amikacin sulfate injection 500mg/2mlDrug listed on formulary (Tier 4)
    ARIKAYCE SUSPENSION 590MG/8.4MLDrug listed on formulary (Tier 5) — Requirements/Limits = PA
    gentamicin sulfate injection 40mg/mlDrug listed on formulary (Tier 4)
    neomycin sulfate tablet 500mgDrug listed on formulary (Tier 2)
    tobramycin sulfate injection 1.2gm/30ml, 80mg/2mlDrug listed on formulary (Tier 4)
    aztreonam injection 1gmDrug listed on formulary (Tier 4)
    clindamycin phosphate injection 300mg/2ml, 600mg/4ml, 900mg/6mlDrug listed on formulary (Tier 2)
    daptomycin injection 500mgDrug listed on formulary (Tier 5)
    1–10 of 20
    1/2
    Formulary entries (no billing codes listed)mixed
    No codes listed
    Formulary requirement codesmixed
    QL(1800 ML per 90 days)quantity limit for citalopram hydrobromide solution 10mg/5ml
    QL(180 EA per 90 days)quantity limit for citalopram hydrobromide tablet 20mg
    QL(360 EA per 90 days)quantity limit for citalopram hydrobromide tablet 10mg
    QL(90 EA per 90 days)quantity limit for citalopram hydrobromide tablet 40mg
    QL(360 EA per 90 days)desvenlafaxine ER 100mg QL
    PAprior authorization required for specific products (e.g., DRIZALMA, FETZIMA, CRESEMBA, POSACONAZOLE DR, VORICONAZOLE, etc.)
    STstep therapy required for specified products (e.g., TRINTELLIX entries list ST)
    QL(180 EA per 90 days); PADRIZALMA 60mg combined QL and PA
    QL(270 EA per 90 days); PADRIZALMA 40mg combined QL and PA
    QL(360 EA per 90 days); PADRIZALMA 30mg combined QL and PA
    1–10 of 34
    1/4
    Sample listed drugs (Antimycobacterials/Antituberculars)NDC | plain
    pyridostigmine bromide tablet 60mglisted drug product and strength
    dapsone tablet 100mg, 25mglisted drug product and strengths
    PRETOMANID TABLET 200MGlisted drug product and strength
    rifabutin capsule 150mglisted drug product and strength
    ethambutol hydrochloride tablet 100mg, 400mglisted drug product and strengths
    isoniazid syrup 50mg/5mllisted drug product and strength
    isoniazid tablet 100mg, 300mglisted drug product and strengths
    PRIFTIN TABLET 150MGlisted drug product and strength
    pyrazinamide tablet 500mglisted drug product and strength
    rifampin capsule 150mg, 300mglisted drug product and strengths
    1–10 of 12
    1/2
    Oncology and specialty listed drugsplain
    ZEPZELCA INJECTION 4MGlisted drug product and strength
    TRECATOR TABLET 250MGlisted drug product and strength
    cyclophosphamide capsule 25mg, 50mglisted drug product and strength
    GLEOSTINE CAPSULE 10MG, 40MG, 100MGlisted drug product and strengths
    LEUKERAN TABLET 2MGlisted drug product and strength
    lomustine capsule 10mg, 40mg, 100mglisted drug product and strengths
    MATULANE CAPSULE 50MGlisted drug product and strength
    VALCHLOR GEL 0.016%listed drug product and strength
    ERLEADA TABLET 240MG, 60MGlisted drug product and strengths
    EULEXIN CAPSULE 125MGlisted drug product and strength
    1–10 of 25
    1/3
    Quantity limit statementsmixed
    QL(84 EA per 365 days)VENCLEXTA STARTING PACK quantity limit
    QL(2.4 ML per 56 days)ABILIFY ASIMTUFII INJECTION 720MG/2.4ML limit
    QL(3.2 ML per 56 days)ABILIFY ASIMTUFII INJECTION 960MG/3.2ML limit
    QL(1 EA per 28 days)ABILIFY MAINTENA injection limit
    QL(180 EA per 90 days)aripiprazole odt tablet disintegrating 15mg limit
    QL(2700 ML per 90 days)aripiprazole solution 1mg/ml limit
    Step therapy flagsmixed
    STStep therapy flag applied to listed products (e.g., ARISTADA, RYTARY, INVEGA series, REXULTI)
    Sample Anxiolytics entriesNDC|formularyCovered
    buspirone hcl tablet 15mgDrug Tier = 2
    buspirone hydrochloride tablet 10mg, 30mg, 5mg, 7.5mgDrug Tier = 2
    meprobamate tablet 200mg, 400mgDrug Tier = 4; Requirements/Limits = PA
    alprazolam tablet 0.25mg, 0.5mg, 1mg, 2mgDrug Tier = 2; Requirements/Limits = QL(150 EA per 30 days); NDS
    clorazepate dipotassium tablet 15mgDrug Tier = 3; Requirements/Limits = QL(180 EA per 30 days); NDS
    diazepam intensol concentrate 5mg/mlDrug Tier = 2; Requirements/Limits = QL(240 ML per 30 days)
    diazepam solution 5mg/5mlDrug Tier = 2; Requirements/Limits = QL(1200 ML per 30 days); NDS
    GLP-1 / weight loss / antidiabetic injectables and oral GLP-1sNDC|formularyCovered
    liraglutide injection 6mg/mlDrug Tier = 2; Requirements/Limits = QL(27 ML per 90 days); PA
    MOUNJARO INJECTION 2.5-15MG/0.5MLDrug Tier = 3; Requirements/Limits = QL(2 ML per 28 days); PA
    OZEMPIC INJECTION 2MG/3ML, 4MG/3ML, 8MG/3MLDrug Tier = 3; Requirements/Limits = QL(3 ML per 28 days); PA
    RYBELSUS TABLET 3MG,7MG,14MGDrug Tier = 3; Requirements/Limits = QL(420/180/90 EA per 90 days respectively); PA
    InsulinsNDC|formularyCovered
    HUMULIN R U-500 INJECTION 500UNIT/MLDrug Tier = 5; Requirements/Limits = PA
    HUMULIN R U-500 KWIKPEN INJECTION 500UNIT/MLDrug Tier = 5; Requirements/Limits = PA
    INSULIN ASPART INJECTION 100UNIT/MLDrug Tier = 3; Requirements/Limits = .
    LANTUS SOLOSTAR INJECTION 100UNIT/MLDrug Tier = 3; Requirements/Limits = .
    AnticoagulantsNDC|formularyCovered
    dabigatran etexilate capsule 150mg, 75mgDrug Tier = 3; Requirements/Limits = QL(180 EA per 90 days)
    ELIQUIS TABLET 2.5MG, 5MG, soluble 0.5MGDrug Tier = 3; Requirements/Limits = various QL values listed
    enoxaparin sodium injection (multiple strengths)Drug Tier = 4; Requirements/Limits = .
    Other blood modifiers / anticoagulantsNDC|formularyCovered
    warfarin sodium tablet (multiple strengths)Drug Tier = 1; Requirements/Limits = .
    XARELTO TABLET 10MG, 15MG, 20MGDrug Tier = 3; Requirements/Limits = QL(90-180 EA per 90 days) with starter pack QL(102 EA per 365 days)
    eltrombopag olamine (multiple forms/strengths)Drug Tier = 5; Requirements/Limits = QL and PA as listed (e.g., QL(186 EA per 31 days); PA)
    Quantity limit examplesmixed
    QL(2700 ML per 90 days)Quantity limit for rivaroxaban suspension reconstituted 1mg/ml
    Formulary annotationsmixed
    QL(102 EA per 365 days)Quantity limit for Xarelto starter pack therapy pack
    QL(180 EA per 90 days)Quantity limit for Xarelto 15mg/2.5mg and VOYDEYA 100mg (also used elsewhere)
    PAPrior authorization required (used for multiple drugs listed)
    High QL examplesmixed
    QL(720 EA per 90 days)Quantity limit example (valsartan, olmesartan and others)
    QL(1440 EA per 90 days)Quantity limit example (benazepril, lisinopril variants)
    Selected branded products with restrictionsNDC/Proprietary (document lists product names)Covered
    OTEZLA XR 75MGOTEZLA XR TABLET EXTENDED RELEASE 24 HOUR 75MG (Tier 5) QL/PA
    OTEZLA 20MG/30MGOTEZLA TABLET 20MG, 30MG (Tier 5) QL/PA
    IV fluids and electrolyte productsmixedCovered
    Dextrose/InjectionsMultiple dextrose and dextrose/saline injection formulations (various concentrations) listed with tiers and no QL
    KCl formulationsMultiple potassium chloride injection and oral formulations listed
    Formulary requirement codes and example QLsmixed
    QL(270 EA per 90 days)Quantity limit example applied to multiple products (e.g., LOKELMA PACKET 5GM, VELTASSA PACKET 8.4GM)
    QL(1620 EA per 90 days)Quantity limit listed for sevelamer carbonate tablet 800mg
    QL(180 EA per 90 days)Quantity limit example (e.g., lubiprostone 24mcg QL)
    QL(90 EA per 90 days)Common QL for many products (e.g., LINZESS, various packets)
    PAPrior Authorization required
    STStep Therapy required
    OVMOther utilization management
    Formulary indicators and quantity limitsmixed
    QL(248 EA per 31 days)Quantity limit for RECORLEV TABLET 150MG
    QL(27 ML per 30 days)Quantity limit for icatibant acetate injection 30mg/3ml
    QL(31 EA per 31 days)Quantity limit for REZDIFFRA TABLET
    QL(8 ML per 28 days)Quantity limit for COSENTYX formulations
    PAPrior authorization required (indicator used throughout)
    OVMOVM indicator (present alongside PA for some injectables)
    inv-37: Quantity limits — multiple explicit example QL values
    Celecoxib (examples)QL(180 EA per 90 days); QL(270 EA per 90 days); QL(540 EA per 90 days)
    Diclofenac external solutionQL(600 ML per 30 days)
    Methadone solutions/tabletsQL examples include QL(3720 ML per 31 days) for solution; QL(372 EA per 31 days) for 10mg tablets; QL(496 EA per 31 days) for 5mg tablets
    Morphine ERQL(93 EA per 31 days)
    Tramadol ERQL(31 EA per 31 days)
    Pioglitazone (example)31 tablets per prescription (standard one-month example)
    inv-38: Quantity limits — additional examples including IMPAVIDO, linezolid suspension, VOQUEZNA, DIFICID
    IMPAVIDO CAPSULE 50mgQL(84 EA per 28 days)
    Linezolid suspension (reconstituted 100mg/5ml)QL(1680 ML per 28 days)
    VOQUEZNA dual/triple pak therapy packQL(336 EA per 90 days); PA
    DIFICID (fidaxomicin) suspension/tabletQL(136 ML per 10 days) for suspension; QL(20 EA per 10 days) for tablet
    Anticonvulsant liquids (selected examples)brivaracetam solution QL(620 ML per 31 days); EPIDIOLEX QL(600 ML per 30 days); FINTEPLA QL(360 ML per 30 days); FYCOMPA suspension QL(720 ML per 30 days)
    inv-39: Sample quantity limits — assorted QL examples
    Levetiracetam disintegrating tablet 250mgQL(1080 EA per 90 days)
    PHENOBARBITAL ELIXIR 20mg/5mlQL(4500 ML per 90 days)
    DIACOMIT packetQL(372 EA per 31 days); PA
    SPRITAM disintegrating 250mgQL(1080 EA per 90 days); PA
    Gabapentin solutionQL(6480 ML per 90 days)
    inv-40: Quantity limits examples — per-product exact QL values
    Citalopram (various forms)QL(1800 ML per 90 days) for solution; QL(180 EA per 90 days) for 20mg tablet; QL(360 EA per 90 days) for 10mg tablet
    DRIZALMA (various strengths)QL(180-540 EA per 90 days) depending on strength; PA
    FETZIMAQL(56 EA per 365 days) for titration pack; QL(180/90 EA per 90 days depending on strength); PA
    Fluoxetine formulationsQL(720 EA per 90 days) for some tablets; QL(1800 ML per 90 days) for solution
    Escitalopram solutionQL(1800 ML per 90 days)

    Prior Authorization, Step Therapy, Documentation, and Denial Risk

    Prior Authorization

    Prior authorization required for specified drugs — overview

    Certain drugs listed on the formulary require prior authorization (PA) from the plan before the prescription will be covered. Providers must obtain plan approval when the Requirements/Limits column for a product includes the PA flag; failure to obtain PA may result in noncoverage.

    • PA = Prior Authorization required before filling the prescription; lack of approval may result in noncoverage (see introduction/definitions).
    Prior Authorization

    Prior authorization required — example ARIKAYCE marked PA

    ARIKAYCE Suspension 590mg/8.4mL is listed with Requirements/Limits = PA; providers must submit a prior authorization request to the plan for coverage of ARIKAYCE.

    • ARIKAYCE SUSPENSION 590MG/8.4ML — Requirements/Limits = PA
    Prior Authorization

    Prior authorization and quantity limits present — providers must submit PA requests and adhere to QL

    Many formulary entries combine prior authorization (PA) and explicit quantity limits (QL); providers must submit PA requests where indicated and ensure requested quantities do not exceed the listed QL values.

    • Examples: IMPAVIDO QL(84 EA per 28 days); linezolid suspension QL(1680 ML per 28 days); VOQUEZNA packs QL(336 EA per 90 days) with PA.
    Prior Authorization

    Prior authorization required — multiple products include 'PA' in Requirements/Limits

    Multiple product rows in the formulary include 'PA' in the Requirements/Limits column, indicating prior authorization is required before coverage; providers should follow the plan's PA process for those products.

    • PA appears alongside many high-tier and specialty products in the formulary table.
    Prior Authorization

    Prior authorization required for specific listed drugs — PA flags in Requirements/Limits

    Selected listed drugs explicitly show 'PA' in the Requirements/Limits field (for example, DRIZALMA, FETZIMA, TRINTELLIX and several antifungals/antineoplastics); providers must obtain prior authorization for these specific products per the formulary.

    • Examples include DRIZALMA entries with QL and PA; voriconazole and posaconazole entries marked PA.
    Prior Authorization

    Prior authorization indicated on multiple products; specific PA criteria not provided in these chunks

    Numerous formulary rows are flagged PA but the extract does not include the detailed clinical PA criteria; providers must submit PA requests using the plan's PA process and supply supporting documentation as requested.

    • PA is shown on many lines without full clinical criteria in this extract; follow the plan's prior authorization program for required information.
    Prior Authorization

    Prior authorization required — multiple listed drugs require PA

    Multiple high-tier and specialty agents are annotated with PA in the formulary (e.g., eltrombopag formulations, PROCRIT, VOYDEYA, ZARXIO); providers must obtain prior authorization before dispensing these products to ensure coverage.

    • Examples: eltrombopag olamine packet/tablet entries include QL and PA; PROCRIT injections list PA.
    Prior Authorization

    Prior authorization required for select drugs — providers must submit PA per plan rules

    For select formulary drugs marked PA, providers must submit a prior authorization request per plan rules; absence of an approved PA may lead to claim denial at time of adjudication.

    • PA flags appear next to many specialty products — obtain authorization before dispensing.
    Prior Authorization

    PA required for select formulary drugs — examples include liraglutide injection and others

    Several GLP‑1 / antidiabetic and weight‑loss injectables and oral GLP‑1 products are listed with PA (examples include liraglutide injection, MOUNJARO, OZEMPIC, RYBELSUS); providers must obtain prior authorization for those products as indicated.

    • liraglutide injection 6mg/mL — Requirements/Limits = QL(27 ML per 90 days); PA
    • MOUNJARO and OZEMPIC entries include QL and PA requirements
    Prior Authorization

    PA required for listed products — examples include eltrombopag formulations

    Eltrombopag formulations are listed with both quantity limits and PA (e.g., packet and tablet forms); providers must request prior authorization and adhere to the stated QL when prescribing eltrombopag.

    • Eltrombopag olamine packet 25mg — QL(186 EA per 31 days); PA
    Prior Authorization

    PA required for select tier 3-4 specialty drugs (examples: NEXLETOL, PRALUENT, VERQUVO)

    Several tier 3–4 specialty agents are annotated with PA (for example NEXLETOL, PRALUENT, VERQUVO); providers must obtain prior authorization prior to dispensing these higher‑tier specialty drugs.

    • NEXLETOL, NEXLIZET, PRALUENT, VERQUVO entries include PA in Requirements/Limits.
    Prior Authorization

    PA required for select agents — list includes many high-tier/specialty agents

    A broad list of high‑tier and specialty agents throughout the formulary carry PA flags; for these agents providers must submit PA requests via the plan’s authorization process to secure coverage.

    • Examples include VERQUVO tablets and multiple specialty injectable agents noted with PA.
    Prior Authorization

    Prior authorization required — indicated in formulary table

    The formulary table includes PA annotations on many product lines; when a product shows PA in Requirements/Limits, providers must obtain prior authorization before filling to avoid coverage denial.

    • Refer to each product row for PA flag and follow plan prior authorization procedures.
    Prior Authorization

    Prior authorization required for selected high-tier drugs (e.g., GATTEX, MYALEPT)

    Selected high‑tier specialty agents (e.g., GATTEX, MYALEPT) are shown with PA in the Requirements/Limits column; providers must obtain PA for these products as specified in the formulary.

    • GATTEX and MYALEPT entries include PA and other utilization flags.
    Prior Authorization

    PA required for selected specialty and high-tier agents — examples provided

    Multiple specialty and high‑tier agents are annotated with PA (examples include octreotide injections, ORGOVYX, RECORLEV); providers must secure prior authorization per the formulary to ensure coverage.

    • Octreotide acetate injection entries — Requirements/Limits = PA; OVM
    Step Therapy

    Step therapy requirements — overview

    Step therapy (ST) may require trying one or more specified drugs first before the plan will cover an alternative; providers should check the Requirements/Limits column for an ST flag and follow the plan's step therapy process.

    • ST = Step Therapy: plan may require trying a specified drug first before covering another.
    Step Therapy

    Step therapy (ST) — plan may require preferred drug trial first

    The formulary uses the ST flag to indicate step therapy; when ST appears for a product, the plan may require a trial of a preferred agent before covering the listed drug.

    • Example: EXXUA entries show ST alongside QL indicating step therapy applies.
    Step Therapy

    Step therapy present — EXXUA examples marked 'ST'

    Some specialty products include 'ST' in Requirements/Limits (for example EXXUA titration pack and EXXUA product lines); providers must follow the step therapy requirement indicated in the formulary when seeking coverage.

    • EXXUA TABLET EXTENDED RELEASE entries — Requirements/Limits = QL(...); ST
    Step Therapy

    Step therapy indicated for select drugs (febuxostat, FETZIMA, TRINTELLIX)

    Certain products are annotated with ST (e.g., febuxostat, FETZIMA, TRINTELLIX), indicating the plan requires step therapy prior to coverage; providers should submit documentation of prior trials when requesting coverage of the nonpreferred drug.

    • FETZIMA entries show QL and PA and ST for some formulations; febuxostat entries list ST.
    Note

    OVM noted — oncology utilization management noted for some agents

    Several oncology and other agents are subject to Oncology Value Management (OVM) in addition to PA; providers may need to follow the OVM process for authorization of these agents.

    • OVM appears alongside PA for many antineoplastics and oncology supportive care drugs.
    Step Therapy

    Step therapy applies to some long-acting injectables and specialty agents

    Step therapy flags apply to several long‑acting injectables and specialty agents (e.g., ARISTADA, INVEGA series, REXULTI) — when ST is indicated providers must document prior use of required agents per the plan's step therapy rules.

    • ARISTADA, INVEGA HAFYERA/INVEGA SUSTENNA/INVEGA TRINZA entries include QL and ST.
    Step Therapy

    Step therapy applies to selected agents — antipsychotics and injectables marked 'ST'

    Selected antipsychotics, long‑acting injectables and other specialty agents are marked ST in the Requirements/Limits column; providers must follow the plan's step therapy sequence (trial of required agents) before the plan will cover the listed product.

    • REXULTI, PERSERIS, risperidone/injectable antipsychotic entries show ST and QL.
    Note

    Step therapy not listed in extract — absence of explicit ST sequences

    This extract does not include explicit step therapy sequences or detailed step‑by‑step algorithms; absence of step order in these pages means providers must consult the plan's PA/ST documentation or contact the plan for the required sequence.

    • No explicit step therapy steps/sequences are provided in this excerpt.
    Note

    Step therapy not specified — products annotated with PA/QL but no sequences

    Many products in the extract are annotated with PA and/or QL but do not show ST sequences; when ST is not specified, providers must still follow PA and QL requirements as listed and contact the plan for any step therapy details.

    • Products annotated with PA/QL but lacking ST sequences require PA or QL adherence; check plan resources for ST details.
    Step Therapy

    Step therapy (ST) on select products — PANCREAZE example

    PANCREAZE capsule strengths are listed with 'ST' in Requirements/Limits — providers must follow the plan's step therapy requirement for coverage of specific PANCREAZE strengths.

    • PANCREAZE CAPSULE DELAYED RELEASE PARTICLES — Requirements/Limits = ST
    Documentation Required

    Exception request documentation — prescriber must provide supporting medical reasons; decision timeframe 72/24 hours

    When requesting an exception (formulary/tiering or to waive PA/ST/QL), the prescriber must provide supporting medical reasons; the plan will decide within 72 hours for standard requests and within 24 hours for expedited requests when warranted.

    • Prescriber must explain medical reasons and provide supporting statement.
    • Standard decision timeframe = 72 hours; expedited = 24 hours if criteria met.
    Documentation Required

    B/D documentation — Part B vs Part D determination may require supporting info

    Some entries are labeled B/D (benefit/dispense or Part B/Part D designation); providers may need to submit information describing the drug's use and setting to determine Part B versus Part D coverage.

    • B/D flag indicates coverage determination may require additional information about setting/use.
    Documentation Required

    PA/QL documentation note — PA and QL entries require supporting documentation

    Formulary rows that include PA and/or QL indicate that prior authorization documentation and adherence to quantity limits must be provided when requesting coverage; providers should submit clinical supporting documentation with PA/QL requests.

    • Submit diagnosis, dose, quantity requested, prior therapy and medical rationale when seeking PA/QL exceptions.
    Documentation Required

    Documentation for PA/NDS — prescribers should supply diagnosis, dose, quantity, and rationale

    When Requirements/Limits list PA or NDS, prescribers should supply supporting documentation per the plan's PA process (including diagnosis, dose, quantity, prior therapy) to meet authorization criteria.

    • NDS = Non-Extended Day Supply; when NDS or PA appears, include rationale for requested supply/days.
    Documentation Required

    Follow plan-specified PA/QL/ST rules — symbols PA/QL/ST/OVM appear in Requirements/Limits

    Providers must follow the plan‑specified Requirements/Limits codes (PA, QL, ST, B/D, OVM) shown in the formulary rows; prescribing or dispensing must comply with these plan rules to obtain coverage.

    • Check the introduction pages for symbol definitions and follow plan PA/QL/ST/OVM processes.
    Note

    Reference to legend for symbol meanings — introduction pages contain abbreviations

    The formulary introduction pages define the abbreviations used in the Requirements/Limits column (e.g., PA, QL, ST, OVM); providers should reference those introduction pages for official definitions.

    • See introduction for PA = Prior Authorization; QL = Quantity Limit; ST = Step Therapy; OVM = Oncology Value Management.
    Documentation Required

    Supporting documentation for QL/ST — injectables and specialty products require documentation

    Some injectable and specialty products that carry QL or ST flags require supporting documentation of medical necessity, dosing frequency, and prior therapy when seeking authorization; include such documentation with PA requests.

    • Examples: injectable long‑acting antipsychotics and specialty injectables list QL and ST and typically require supporting documentation.
    Prior Authorization

    PA noted for select insulins — concentrated insulins may require PA

    Concentrated insulin products such as HUMULIN R U‑500 are listed with PA; providers must submit prior authorization documentation for these insulin formulations before coverage will be approved.

    • HUMULIN R U-500 (CONCENTRATED) INJECTION 500UNIT/ML — Requirements/Limits = PA
    Documentation Required

    Documentation hints — injectable biologics marked PA/OVM require additional review

    Injectable biologics and supportive agents marked with PA and/or OVM often require additional documentation or on‑site verification/management review at authorization; providers should include required clinical and site‑of‑care details with PA submissions.

    • NEULASTA / NEULASTA ONPRO entries — Requirements/Limits = PA; OVM
    Billing Rule

    Align dispensing with QL — ensure dispensed amount matches QL entries

    Prescribers and pharmacies should ensure dispensed amounts align with the formulary quantity limits (QL) shown for each product; requests that exceed the stated QL may be denied or require an override/exception.

    • Example QLs to follow when dispensing: QL(180 EA per 90 days), QL(31 EA per 31 days), QL(360 GM per 90 days).
    Prior Authorization

    Submit PA and respect QL — items marked PA/QL require prior authorization and adherence to limits

    For products annotated with PA and/or QL, providers must submit the required prior authorization and supporting clinical documentation; failure to obtain PA or to adhere to QL may result in denial of coverage at claim adjudication.

    • Not obtaining required PA may result in the plan not covering the drug.
    • Claims exceeding QL without authorization may be denied.
    Documentation Required

    PA documentation examples — calcipotriene, deferasirox examples

    Examples in the formulary show PA documentation is required for specific products (e.g., calcipotriene topical formulations, deferasirox, AURYXIA, tolvaptan, trientine); providers should include clinical rationale and requested quantity when submitting PA requests.

    • CALCIPOTRIENE OINTMENT/SOLUTION entries — QL with PA; include indication and quantity in PA submission.
    Documentation Required

    Prior authorization/step therapy documentation — PA or ST require documentation as specified

    Products labeled with PA or ST will require the corresponding prior authorization or step therapy documentation as specified on the formulary table; submit the requested clinical information to support authorization.

    • PANCREAZE (ST) and PROLASTIN‑C (PA) illustrate ST vs PA documentation needs.
    Documentation Required

    Documentation for QL/PA requests — providers must submit supporting clinical documentation

    When requesting authorization for agents annotated with QL and PA, the provider must submit documentation supporting the requested quantity and medical necessity consistent with the payer's prior authorization process.

    • Include diagnosis, dose, frequency, prior therapies tried, and rationale for quantity exceeding standard QL when applicable.
    Denial Risk

    Prior Authorization requirement — not obtaining required PA may result in noncoverage

    Prior authorization is required for many products in the formulary; not obtaining an approval when PA is indicated may cause the plan to deny coverage for the drug.

    • PA requirement is defined in the formulary introduction: lack of approval may result in noncoverage.
    Denial Risk

    Prior Authorization requirement — failure to obtain PA may result in noncoverage

    If prior authorization is required for a drug and the provider does not secure approval, the plan may not cover the drug and the claim can be denied; obtain PA before dispensing where the Requirements/Limits column shows PA.

    • Check each product row for PA flags and follow the plan's prior authorization procedures.
    Denial Risk

    PA required for select agents — ARIKAYCE example

    ARIKAYCE Suspension 590mg/8.4mL is listed with Requirements/Limits = PA; dispensing without an approved PA may trigger denial of coverage for ARIKAYCE.

    • ARIKAYCE SUSPENSION 590MG/8.4ML — Requirements/Limits = PA
    Denial Risk

    Quantity limits and PA may cause denial — examples where QL/PA not met may trigger denial

    When QL or PA requirements are not met (for example, prescribing beyond the stated QL or dispensing a PA‑flagged product without approval), the claim may be denied; providers should check QL values and obtain PA ahead of dispensing.

    • Examples: VOQUEZNA packs, linezolid suspension, IMPAVIDO, DIFICID show QL and/or PA that, if not followed, may cause denial.
    Prior Authorization

    Prior authorization indicated — PA flag requires authorization

    Products listed with 'PA' in the Requirements/Limits field require prior authorization; failure to obtain PA may result in claim denial at time of adjudication.

    • Refer to the Requirements/Limits column for PA flags and follow the plan's PA submission process.
    Denial Risk

    Quantity limit exceedance — exceeding QL may trigger denial or require override

    If the requested quantity exceeds the stated quantity limit (QL) without an approved override or exception, the claim may be denied or require prior authorization to exceed the limit.

    • Example QLs: QL(1080 EA per 90 days); requests beyond these limits need justification or PA.
    Denial Risk

    Prior authorization required for some products — DRIZALMA, FETZIMA, TRINTELLIX examples

    Several commonly prescribed agents (e.g., DRIZALMA, FETZIMA, TRINTELLIX) are designated PA in the formulary; dispensing these formulations without PA may lead to coverage denial.

    • DRIZALMA sprinkle capsule entries list QL and PA across strengths.
    Note

    Presence of 'PA' indicates authorization required — absence implies no PA on that line

    The presence of 'PA' next to a product line signals that prior authorization is required for that product; if 'PA' is absent for a line there is no PA indicated on that line.

    • Check the Requirements/Limits column for PA to determine whether PA is required for a given product.
    Denial Risk

    PA/QL noncompliance may trigger denial — unmet PA/QL can be denied

    Requests for drugs listed with PA or QL may be denied if authorization is not obtained or the requested quantity exceeds the plan's limit; providers should secure PA and document adherence to QL to avoid denial.

    • PA/QL noncompliance is a common denial trigger at adjudication.
    Denial Risk

    Denial triggers from utilization controls — PA/ST/QL presence may cause denial

    Utilization controls shown in the formulary (PA, ST, QL) are potential denial triggers; when a drug is listed with these controls providers must obtain authorization or adhere to limits to avoid claim denials.

    • Claims may be denied or require prior authorization when PA, ST, or QL are present and not satisfied.
    Prior Authorization

    Prior authorization required for some agents — liraglutide injection example

    Products annotated with PA (examples: liraglutide injection, MOUNJARO, OZEMPIC) require prior authorization; dispensing without PA may cause a denial or noncoverage determination.

    • GLP‑1 injectables in the extract show both QL and PA requirements.
    Denial Risk

    PA-required items — coverage may be denied if PA not obtained

    If a product line lists 'PA' the plan may deny coverage if the provider does not obtain prior authorization; providers should obtain PA prior to dispensing to prevent denials.

    • PA requirement defined in formulary introduction: lack of approval may result in noncoverage.
    Prior Authorization

    PA required for selected products — NEXLETOL, PRALUENT, VERQUVO examples

    Many high‑tier specialty drugs (e.g., NEXLETOL, PRALUENT, VERQUVO) are annotated with PA in the formulary; providers must secure prior authorization for coverage of these medications.

    • NEXLETOL and PRALUENT entries include QL and PA flags.
    Note

    PA indicated in table rows — some rows show PA flag without full detail

    Some formulary table rows show PA without accompanying clinical detail; providers should treat any PA flag as requiring authorization and consult plan resources for specific PA submission requirements.

    • PA = . entries indicate PA may apply and require follow-up to determine clinical criteria.
    Denial Risk

    PA and QL triggers — coverage may be denied or limited when PA/QL present

    When products are marked with PA and/or QL, coverage may be denied or limited if prior authorization is not obtained or quantities exceed the listed limits; providers should verify PA and QL before dispensing.

    • Examples of denial risk include OTEZLA QL/PA and other calcipotriene QL/PA entries.
    Denial Risk

    Denial risk for unmet QL/PA — claims may be denied if QL/PA requirements are not met

    Claims may be denied if QL or PA requirements listed for a drug are not met; providers should confirm authorization status and ensure quantities conform to the QL to reduce denial risk.

    • Denial examples include OTEZLA, calcipotriene topical formulations and other PA/QL products.
    Note

    Authorization/denial triggers noted by product — presence of PA/ST/OVM/QL drives authorization

    Presence of utilization controls (PA, ST, OVM, QL) on specific products determines whether authorization is needed; providers should treat these flags as actionable requirements and follow the plan's processes to obtain authorization.

    • PA, ST, OVM and QL flags drive authorization requirements and site‑of‑care considerations (e.g., infusion center/OVM).
    Prior Authorization

    Prior authorization required for specified agents — PA or PA; OVM require authorization

    Drugs listed with 'PA' or 'PA; OVM' will require prior authorization; providers must obtain the required PA prior to dispensing or risk denial at adjudication.

    • Examples: octreotide acetate injections and NEULASTA ONPRO listed with PA; OVM.

    Step Therapy Rules and Affected Products

    Coverage ruleDescription
    Step therapy (ST)
    Plan may require trying specified drug(s) first before covering an alternative for the same condition (i.e., must try preferred agent(s) first).
    PresenceExample / Note
    Some drugs are subject to step therapy
    Formulary lines show 'ST' alongside Requirements/Limits for certain products (e.g., EXXUA entries show QL(...); ST).
    ProductFormulary annotation
    EXXUA titration pack / EXXUA extended‑release tablets
    {"text":"Requirements/Limits include QL(...) and 'ST' indicating step therapy applies to EXXUA titration pack and EXXUA products."
    status":""}
    High-tier productStep therapy annotation
    febuxostat (40mg, 80mg)
    {"text":"Listed with QL(90 EA per 90 days); ST — step therapy required as indicated on formulary."
    status":""}
    SituationFormulary requirement
    Oncology targeted agents and supportive care
    Many oncology targeted agents are annotated with PA and often OVM (Oncology Value Management) requiring prior authorization and OncoHealth review; step therapy algorithms are not detailed.
    Agent examplesStep therapy / annotation
    RYTARY (various ER strengths)
    {"text":"Requirements/Limits include QL(...); ST — step therapy flag present for RYTARY."
    status":""}
    Class / productStep therapy indicator
    Long-acting injectable antipsychotics and select antipsychotics (e.g., ARISTADA, INVEGA series)
    Multiple long-acting injectables and antipsychotics are listed with 'ST' in Requirements/Limits indicating step therapy applies prior to coverage (examples: ARISTADA, INVEGA HAFYERA/SUSTENNA/TRINZA entries include ST).
    GLP-1 injectables / oral GLP-1sStep therapy / prior auth
    MOUNJARO; OZEMPIC; liraglutide; RYBELSUS
    No explicit step therapy sequences are shown in the extract for GLP‑1 injectables/oral GLP‑1s; several are annotated with PA and QL (e.g., MOUNJARO QL(2 ML per 28 days); PA; OZEMPIC QL(3 ML per 28 days); PA).
    ST sequences provided?Document note
    No explicit ST sequences in extract
    The formulary excerpt lists products with annotations such as PA and QL but does not provide step-by-step ST sequences or algorithms for the listed products; see individual Requirements/Limits flags.
    High-tier agentAuthorization / QL
    tolvaptan (15mg, 30mg)
    {"text":"Listed with QL(...) and PA (e.g., QL(124 EA per 31 days); PA) — step therapy specifics are not provided in this segment."
    status":""}
    ProductStep therapy annotation
    PANCREAZE (multiple capsule strengths)
    Formulary shows PANCREAZE entries with 'ST' in Requirements/Limits indicating a step therapy requirement for certain pancreatic enzyme strengths.

    Quantity Limits and Per-Product Examples

    inv-168: Example QL for pioglitazone (31 tablets per prescription)
    Pioglitazone (illustrative)31 tablets per prescription (example provided in formulary text)
    ContextQuantity limits can be expressed as EA or ML per specified time period and may supplement monthly or 90-day supplies
    Where listedQL values appear in the Requirements/Limits column of the formulary table
    inv-169: Multiple listed drug QLs (celecoxib, methadone soln, morphine ER, buprenorphine products)
    Celecoxib capsulesQL examples: 180 EA / 90 days (200/400mg), 270 EA / 90 days (100mg), 540 EA / 90 days (50mg)
    Methadone solutions/tabletsSolution QL examples include QL(3720 ML per 31 days); tablet QL examples include QL(372 EA per 31 days)
    Morphine ERQL(62 EA per 31 days) for many ER strengths; some morphine entries show higher ML limits for solutions
    Buprenorphine patchQL(4 EA per 28 days); NDS
    KLOXXADO liquidQL(12 EA per 90 days)
    inv-170: IMPAVIDO CAPSULE 50MG QL(84)
    IMPAVIDO CAPSULE 50MGQL(84 EA per 28 days)
    TierListed as Drug Tier = 5 in formulary table
    LocationRequirements/Limits column shows the QL per 28 days
    inv-171: linezolid suspension reconstituted 100mg/5ml QL(1680)
    Linezolid suspension reconstituted 100mg/5mlQL(1680 ML per 28 days)
    Linezolid tablet 600mgQL(56 EA per 28 days)
    TieringSuspension listed as Tier 5; injection/tablet strengths vary by tier
    inv-172: VOQUEZNA therapy pack QL(336)
    VOQUEZNA dual/triple pak therapy packQL(336 EA per 90 days); PA
    FormulationsDual and Triple therapy packs both show same QL and PA flag
    TierListed in formulary as Drug Tier = 4
    inv-173: DIFICID suspension/tablet QL examples
    DIFICID suspension (40mg/ml)QL(136 ML per 10 days)
    DIFICID tablet 200mgQL(20 EA per 10 days)
    Indication in tableListed as Drug Tier = 5 with QL specified in Requirements/Limits column
    inv-174: Anticonvulsant liquids and FINTEPLA/FYCOMPA QLs examples
    Brivaracetam solution 10mg/mlQL(620 ML per 31 days)
    EPIDIOLEX solution 100mg/mlQL(600 ML per 30 days); PA
    FINTEPLA solution 2.2mg/mlQL(360 ML per 30 days); PA
    FYCOMPA suspension 0.5mg/mlQL(720 ML per 30 days); PA
    inv-175: brivaracetam solution 10mg/ml QL(620 ML per 31 days)
    Brivaracetam solution 10mg/ml (example)QL(620 ML per 31 days)
    Related noteEntry also shows PA in Requirements/Limits column
    ContextListed under Anticonvulsants in formulary
    inv-176: LEVETIRACETAM TABS DISINTEGRATING 250MG QL(1080 EA per 90 days)
    LEVETIRACETAM tablet disintegrating 250mgQL(1080 EA per 90 days); PA
    Other strengths500mg QL(540 EA per 90 days)
    SectionListed under Anticonvulsants in formulary
    inv-177: PHENOBARBITAL ELIXIR QL(4500 ML per 90 days)
    PHENOBARBITAL ELIXIR 20mg/5mlQL(4500 ML per 90 days)
    Memantine solution 2mg/mlQL(1080 ML per 90 days)
    Clinical contextLiquid and elixir formulations have ML-based QLs expressed per 90 days
    inv-178: memantine solution QL(1080 ML per 90 days)
    Memantine hydrochloride solution 2mg/mlQL(1080 ML per 90 days)
    Memantine ER capsules/tabletsQL examples: QL(90 EA per 90 days) for some ER formulations; PA noted for certain forms
    Listing locationAntidementia Agents section of formulary
    inv-179: Multiple per-line QL entries — various examples across many drugs
    Representative multi-line QL examplesExamples across sections include QL(180 EA per 90 days), QL(360 EA per 90 days), QL(3 ML per 84 days), QL(175 EA per 31 days)
    Where usedThese appear throughout antidepressant, anticonvulsant, antifungal and other classes in Requirements/Limits column
    ImplicationProviders should check the specific row for exact QL units and time window
    inv-180: PRETOMANID TABLET 200MG QL(90 EA per 90 days)
    PRETOMANID TABLET 200MGQL(90 EA per 90 days)
    SectionListed under Antimycobacterials/Antituberculars
    PAPA flag present on some related antituberculars in the table
    inv-181: lenalidomide capsule QL(31 EA per 31 days)
    Lenalidomide capsule (various strengths)QL(31 EA per 31 days); PA
    Therapy areaListed under Antineoplastics (lenalidomide entries) with PA and QL
    Usage noteQuantity limits correspond to a typical monthly supply for these agents
    inv-182: ROZLYTREK CAPSULE 200MG QL(93 EA per 31 days)
    ROZLYTREK CAPSULE 200MGQL(93 EA per 31 days); PA; OVM
    ROZLYTREK other strengthsAlso listed with PA/OVM for other strengths; QL shown for 200mg
    SectionOncology formulary entries (PA; OVM)
    inv-183: VENCLEXTA STARTING PACK QL(84 EA)
    VENCLEXTA starting pack (therapy pack)QL(84 EA per 365 days); PA; OVM
    VENCLEXTA tabletsStarting pack distinct from regular tablets which are PA/OVM-listed
    PlacementListed in oncology/specialty section with OVM
    inv-184: RUBRACA TABLET QL(124 EA per 31 days)
    RUBRACA tablet (various strengths)QL(124 EA per 31 days); PA; OVM
    Oncology noteListed with PA and oncology value management in Requirements/Limits
    Time window31-day QL corresponds to monthly coverage cap in formulary
    inv-185: VENCLEXTA STARTING PACK QL(84 EA)
    VENCLEXTA starting pack (duplicate line)QL(84 EA per 365 days)
    Formulary locationOncology/specialty drug table (PA; OVM)
    Coverage implicationYearly QL for starting pack limits how many starter packs are covered per year
    inv-186: ABILIFY ASIMTUFII INJECTION QL examples (2.4 ML)
    ABILIFY ASIMTUFII injection 720mg/2.4mlQL(2.4 ML per 56 days)
    ABILIFY ASIMTUFII injection 960mg/3.2mlQL(3.2 ML per 56 days)
    Dose/interval noteQL expressed as ML per 56 days for these long-acting injectables
    inv-187: ABILIFY ASIMTUFII INJECTION other strength QL (3.2 ML)
    ABILIFY ASIMTUFII injection 960mg/3.2mlQL(3.2 ML per 56 days)
    Related entriesOther aripiprazole long-acting injectables show ML-based QLs per dosing window
    Prior auth/step therapySome injections are subject to ST in Requirements/Limits
    inv-188: INVEGA HAFYERA INJECTION QL(3.5 ML)
    INVEGA HAFYERA injection 1092mg/3.5mlQL(3.5 ML per 180 days); ST
    INVEGA HAFYERA 1560mg/5mlQL(5 ML per 180 days); ST
    Dosing intervalQLs reflect long-acting injection dosing windows (180 days)
    inv-189: OPIPZA FILM 10MG QL(90)
    OPIPZA FILM 10mgQL(90 EA per 30 days)
    PERSERIS injection 120mg/90mgQL(1 EA per 30 days); ST
    REXULTI tablets 3/4mgQL(31 EA per 31 days); ST
    inv-190: PERSERIS INJECTION QL(1)
    PERSERIS injection 120mg/90mgQL(1 EA per 30 days); ST
    REXULTI tablet 3mg/4mgQL(31 EA per 31 days); ST
    Risperidone solutionListed separately with ML-based QL elsewhere (see risperidone solution entry)
    inv-191: REXULTI 3/4MG QL(31)
    REXULTI tablets (3mg/4mg)QL(31 EA per 31 days); ST
    REXULTI (other strengths)Some strengths show QL(62 EA per 31 days)
    Highlighted entryREXULTI 3/4mg QL(31 EA per 31 days)
    inv-192: risperidone solution QL(720)
    Risperidone solution 1mg/mlQL(720 ML per 90 days)
    Risperidone ODT/tablet entriesMultiple tablet/ODT QLs listed in adjacent rows (EA per 90 days)
    SectionAntipsychotics class in formulary
    inv-193: clozapine odt tablet 100mg QL(810)
    Clozapine ODT 100mgQL(810 EA per 90 days)
    Clozapine other strengthsOther ODT strengths have different QLs (e.g., 135 EA per 30 days)
    Clinical noteHigh QL for ODT reflects chronic treatment needs and monitoring requirements
    inv-194: PREVYMIS packet/tablet QL examples
    PREVYMIS packet 120mg/20mgQL(112 EA per 28 days); PA
    PREVYMIS tablet 240/480mgQL(28 EA per 28 days); PA
    Formulary locationAntivirals / CMV agents section
    inv-195: BIKTARVY TABLET QL(31)
    BIKTARVY tabletQL(31 EA per 31 days)
    ClassAntiretroviral agents (HIV) section
    ImplicationStandard monthly QL for HIV combination therapies
    inv-196: oseltamivir phosphate solutions QL(84-168)
    Oseltamivir phosphate (capsules) 30/45/75mgQL examples: QL(84 EA per 180 days) for some strengths; QL(168 EA per 180 days) for others
    Oseltamivir suspension 6mg/mlQL(1050 ML per 180 days)
    SectionAntiinfluenza agents in formulary
    inv-197: diazepam solution QL(1200)
    Diazepam solution 5mg/5mlQL(1200 ML per 30 days)
    Diazepam tabletsSome tablet strengths show QL(120 EA per 30 days)
    NDS noteBenzodiazepine entries often include NDS/dispensing limits in Requirements/Limits
    inv-198: alprazolam tablet QL(150)
    Alprazolam tablet (various strengths)QL(150 EA per 30 days); NDS
    Benzodiazepines class noteMultiple benzodiazepine entries show 30-day QLs and NDS designation
    Provider actionPrescribers should adhere to QL and NDS when dispensing
    inv-199: MOUNJARO INJECTION QL(2)
    MOUNJARO injection (all strengths)QL(2 ML per 28 days); PA
    Dose window28-day ML-based QL reflecting monthly supplies for GLP-1 injectables
    TieringListed as Drug Tier = 3 with PA
    inv-200: OZEMPIC INJECTION QL(3)
    OZEMPIC injection (various strengths)QL(3 ML per 28 days); PA
    GLP-1 class noteMonthly ML QLs common for GLP-1 injectables (OZEMPIC, MOUNJARO, liraglutide)
    Provider actionPrior authorization required where PA is listed
    inv-201: HUMULIN R U-500 concentrated insulin listed with PA noted in some chunks
    HUMULIN R U-500 concentrated insulinRequirements/Limits = PA (prior authorization required)
    KwikPen formulationAlso listed with PA in Requirements/Limits (HUMULIN R U-500 KWIKPEN)
    DocumentationPA documentation required for concentrated insulin per formulary notes
    inv-202: rivaroxaban suspension QL(2700 ML)
    Rivaroxaban suspension reconstituted 1mg/mlQL(2700 ML per 90 days)
    Formulation noteSuspension QLs expressed in ML for oral suspensions
    SectionAnticoagulants class in formulary
    inv-203: XARELTO STARTER PACK QL(102 EA)
    XARELTO starter pack therapy packQL(102 EA per 365 days)
    XARELTO 15mg/2.5mgQL(180 EA per 90 days)
    XARELTO 10mg/20mgQL(90 EA per 90 days)
    inv-204: XARELTO 15/2.5MG QL(180)
    XARELTO 15mg/2.5mgQL(180 EA per 90 days)
    Use noteCommon 90-day QL for starter/transition supplies
    TierListed as Drug Tier = 3
    inv-205: XARELTO 10/20MG QL(90)
    XARELTO 10mg/20mgQL(90 EA per 90 days)
    Standard QL90 EA per 90 days corresponds to typical 3-month supply cap
    Formulary noteCheck starter pack QL separate from regular tablet QL
    inv-206: eltrombopag packet QL(186)
    Eltrombopag olamine packet 25mgQL(186 EA per 31 days); PA
    Other packet strengthsQL(62 EA per 31 days) for some strengths; PA indicated
    Therapy areaBlood products/modifiers section
    inv-207: tranexamic acid tablet QL(90 EA)
    Tranexamic acid tablet 650mgQL(90 EA per 63 days)
    Time windowListed per 63 days in the table for this strength
    SectionHemostasis agents in formulary
    inv-208: valsartan tablet QL(720)
    Valsartan tablets (various strengths)QL examples include QL(720 EA per 90 days) for select strengths
    Benazepril 5mg tabletQL(1440 EA per 90 days)
    Highlighted entryValsartan QL(720 EA per 90 days)
    inv-209: benazepril tablet QL(1440)
    Benazepril hydrochloride tablet 5mgQL(1440 EA per 90 days)
    Other benazepril strengthsMultiple QLs (90-720 EA per 90 days) depending on strength
    Therapeutic classACE inhibitors in formulary
    inv-210: amlodipine/atorvastatin combos QL(90-180)
    Amlodipine/atorvastatin combination productsQL(180 EA per 90 days) or QL(90 EA per 90 days) depending on strength
    Formulary locationCardiovascular combinations section
    NoteStrength-dependent QL shown in Requirements/Limits column
    inv-211: Loop/thiazide diuretics QL(31 EA per 31 days)
    Loop and thiazide diuretics (many oral agents)Standard QL shown as QL(31 EA per 31 days)
    Typical useApplies to many common oral diuretics and short-term fills
    Provider actionDispense per QL to avoid claim denial
    inv-212: PRALUENT INJECTION QL(2 ML per 28 days)
    PRALUENT injection 150mg/75mgQL(2 ML per 28 days); PA
    Administration notePA indicated in Requirements/Limits column; ML-based QL reflects injection volume per month
    Therapeutic areaLipid-lowering injectable (PCSK9) section
    inv-213: CORLANOR SOLUTION QL(1350 ML per 90 days)
    CORLANOR solution 5mg/5mlQL(1350 ML per 90 days)
    Formulary locationAntiarrhythmics/cardiac agents section
    Coverage implication90-day ML-based QL limits total dispensed solution per quarter
    inv-214: VERQUVO TABLET 10MG QL(30 EA per 30 days)
    VERQUVO tablet 10mgQL(30 EA per 30 days); PA
    Other strengthsQL(60 EA per 30 days) for other strengths as listed
    Therapeutic classHeart failure agents section
    inv-215: Various listed QL examples across many drugs
    Representative multi-product QLsExamples across the formulary include QL(90 EA per 90 days); QL(180 EA per 90 days); QL(31 EA per 31 days); ML/GM limits for liquids/creams
    ApplicabilityThese QL patterns recur in many therapeutic sections (e.g., dermatologic, CNS, cardiovascular)
    Provider noteCheck the specific product row for exact unit/time window
    inv-216: VERQUVO multiple strengths QL examples
    VERQUVO multiple strengthsQL(30 EA per 30 days) for 10mg; QL(60 EA per 30 days) for other strengths; PA indicated
    Coverage notePA required where listed in Requirements/Limits
    Formulary locationCardiovascular agents section
    inv-217: fluocinolone formulations QL(360 GM/ML per 90 days)
    Fluocinolone acetonide topical formulationsQL(360 GM or ML per 90 days) for many formulations; some lower-strength entries QL(180 GM per 90 days)
    Fluocinonide examplesFluocinonide cream/ointment/solution entries show QL(180 GM or ML per 90 days)
    Dermatology noteTopical steroid QLs are expressed as GM (cream/gel) or ML (solution) per 90 days
    inv-218: OTEZLA XR 75MG QL(31)
    OTEZLA XR 75mgQL(31 EA per 31 days); PA
    OTEZLA other presentationsOTEZLA therapy pack entries also list QL/PA in Requirements/Limits
    Therapeutic classPDE4 inhibitor/psoriasis/psoriatic arthritis agents section
    inv-219: ciclopirox gel/shampoo QL(180-360)
    Ciclopirox formulations (gel/shampoo/suspension)QL range QL(180-360 GM/ML per 90 days) depending on formulation
    Formulation-specific QLGel typically QL(300 GM per 90 days) in other entries; shampoo QL(360 ML per 90 days)
    Dermatology sectionTopical antifungals listed with GM/ML QLs
    inv-220: LOKELMA/VELTASSA packet QLs
    LOKELMA/VELTASSA packetsExamples include LOKELMA PACKET 5GM QL(270 EA per 90 days); LOKELMA PACKET 10GM QL(94 EA per 90 days); VELTASSA PACKET 8.4GM QL(270 EA per 90 days)
    Packet-based QLsPackets counted as EA per 90 days in Requirements/Limits column
    Therapeutic areaPotassium binders and related GI agents section
    inv-221: LOKELMA PACKET 5GM QL(270)
    LOKELMA PACKET 5GMQL(270 EA per 90 days)
    Formulary noteListed under Potassium Binders with 90-day QL
    Provider actionDispense per packet QL to avoid override/denial
    inv-222: LOKELMA PACKET 10GM QL(94)
    LOKELMA PACKET 10GMQL(94 EA per 90 days)
    Alternate packet sizeSmaller packet count results in different 90-day QL
    SectionPotassium binders
    inv-223: VELTASSA PACKET 8.4GM QL(270)
    VELTASSA PACKET 8.4GMQL(270 EA per 90 days)
    Other VELTASSA sizesVELTASSA 16.8GM packet QL(90 EA per 90 days) shown elsewhere
    Therapeutic areaPotassium binders section
    inv-224: LINZESS CAPSULE QL(90)
    LINZESS capsule (145/290/72mcg)QL(90 EA per 90 days)
    Lubiprostone 24mcgQL(180 EA per 90 days)
    GI agents sectionCommon 90-day QLs for chronic GI medications
    inv-225: lubiprostone capsule QL(180)
    Lubiprostone capsule 24mcgQL(180 EA per 90 days)
    Alternate strengthsOther strengths may have different QLs listed nearby
    Formulary sectionConstipation/GI agents
    inv-226: esomeprazole DR QL(180)
    Esomeprazole magnesium DR capsule 20/40mgQL(180 EA per 90 days)
    Pantoprazole DR tabletQL(180 EA per 90 days) (see related entry)
    PPI class noteCommon 90-day QL for proton pump inhibitors
    inv-227: VYNDAQEL CAPSULE QL(124)
    VYNDAQEL capsule 20mgQL(124 EA per 31 days); PA
    Therapy areaGenetic/protein disorder therapies section
    Coverage notePA indicated in Requirements/Limits column
    inv-228: pantoprazole sodium DR QL(180)
    Pantoprazole sodium DR tablet 20/40mgQL(180 EA per 90 days)
    Esomeprazole comparisonEsomeprazole and pantoprazole share similar 90-day QLs in formulary
    Provider noteDispense per 90-day QL for chronic PPI therapy
    inv-229: oxybutynin ER QL(180)
    Oxybutynin chloride ER 10/15/5mgQL(180 EA per 90 days)
    Alternative formulationsOxybutynin solution/tablet entries listed with other QLs or none
    Therapeutic classUrinary antispasmodics and overactive bladder agents
    inv-230: testosterone pump gel 1.62% QL(450)
    Testosterone pump gel 1.62%QL(450 GM per 90 days)
    Testosterone pump gel 1%QL(900 GM per 90 days)
    HighlightedTestosterone pump gel 1% QL(900 GM per 90 days)
    inv-231: testosterone pump gel 1% QL(900)
    Testosterone pump gel 1%QL(900 GM per 90 days)
    1.62% formulationQL(450 GM per 90 days)
    PASome testosterone pump entries show PA in Requirements/Limits elsewhere
    inv-232: etonogestrel/ethinyl ring QL(3 EA per 84 days)
    Etonogestrel/ethinyl estradiol ringQL(3 EA per 84 days)
    Long-acting contraceptive QLRing QL corresponds to typical 3-month replacement schedule
    Formulary sectionHormonal agents/contraceptives
    inv-233: various oral contraceptives QL(91)
    Various oral contraceptives (examples)QL(91 EA per 91 days) for many oral contraceptives such as ashlyna, camrese lo, daysee, etc.
    Supply window91-day QL supports quarterly dispensing/90+1 day cycles per formulary
    Class noteApplies to many combined oral contraceptives listed
    inv-234: REZDIFFRA TABLET QL(31)
    REZDIFFRA tabletQL(31 EA per 31 days); PA
    PlacementListed under thyroid/hormonal agents with PA for some strengths
    Monthly QLStandard 31-day QL applied
    inv-235: RECORLEV TABLET 150MG QL(248)
    RECORLEV tablet 150mgQL(248 EA per 31 days); PA
    Therapy areaHormonal/antineoplastic supportive agents section
    Provider noteHigh EA per 31 days reflects dosing regimen; PA present
    inv-236: icatibant injection QL(27 ML per 30 days)
    Icatibant acetate injection 30mg/3mlQL(27 ML per 30 days); PA
    Unit interpretation27 ML per 30 days corresponds to nine 3ml injections or equivalent dosing window
    SectionAngioedema agents/HAE section
    inv-237: COSENTYX QL(4-8 ML per 28 days)
    COSENTYX formulationsQL(4-8 ML per 28 days) depending on formulation; PA
    Dose forms75mg/150mg pens/prefilled syringes mapped to ML-based QLs per 28-day dosing
    Therapeutic classImmunological/biologics (psoriasis/autoimmune) section

    Site of Care and Infusion Center Notes

    Note

    Infusion center / OVM notes — OVM applied to some injectables indicating site/administration oversight

    Some formulary injectables require infusion‑center oversight or OVM review (OVM flag); providers should coordinate site‑of‑care documentation and OVM submission requirements when seeking authorization for these agents.

    • OVM = Oncology Value Management — administered by OncoHealth; additional information required for antineoplastics/supportive care.

    Biosimilar and Interchangeable Biologic Notes

    Billing Rule

    Original biological product — plan may add interchangeable biosimilar and move original product between tiers

    The plan may immediately add an interchangeable biosimilar and move or remove the original biological product from the formulary or change its tier; providers should be aware that such substitutions can occur without advance notice and may affect coverage.

    • Interchangeable biosimilars may be substituted at the pharmacy without a new prescription depending on state law.
    Billing Rule

    NEULASTA / ZARXIO — biosimilar included but may require PA/OVM

    ZARXIO (a biosimilar to NEULASTA) is listed with PA and OVM in the formulary; providers should anticipate that biosimilars may require PA/OVM review and include necessary documentation when requesting authorization.

    • ZARXIO INJECTION entries — Requirements/Limits = PA; OVM

    Background and Scope

    This formulary groups drugs by medical condition and lists each product with a Drug Tier and any applicable Requirements/Limits (for example, PA for prior authorization, QL for quantity limits, and ST for step therapy). Coverage for a listed drug depends on meeting those per‑product requirements and dispensing at network pharmacies; the document also explains policies for biosimilars and temporary transition supplies (standard temporary supply = 31 days) and directs providers to the introduction pages for symbol definitions and exception processes.